About us

Bionevia Pharmaceuticals Inc. is a company that focuses on the discovery, development, and commercialization of products in the Central Nervous System (CNS) and Oncology therapeutic areas.

Currently, the company has programs targeting the following conditions:

• Diabetic neuropathy (BNV-222) - disease modifying agent
• Cancer and acute pain (BNV-220)
• Multiple myeoloma (BNV-215)

The company has already signed out-licensing agreements for two of these programs: BNV-222 and BNV-220.